Stanford University · NeuroscienceLansberg Lab
Maarten G Lansberg · Stanford, California
Research Focus
Dr. Maarten G Lansberg's lab at Stanford University focuses on improving prevention strategies for stroke recurrence. They are conducting the CLARITY trial, which aims to evaluate whether adding cilostazol to standard treatment can significantly lower the risk of further strokes and cardiovascular events in a diverse population. This research is vital as it seeks to address the underutilization of cilostazol in the United States, potentially benefiting millions of stroke survivors with a safe and affordable treatment option.
cilostazolischemic strokesecondary preventioncardiovascular eventsclinical trialsdual antiplatelet therapystroke recurrenceNINDSlong-term follow-uppublic health
Research Aims
4AIM 01Evaluate the effectiveness of cilostazol in preventing recurrent strokes.
AIM 02Assess the overall reduction in major cardiovascular events for patients receiving cilostazol.
AIM 03Investigate the diverse population's response to long-term cilostazol treatment after stroke.
AIM 04Facilitate broad enrollment strategies in clinical trials to ensure diversity among participants.
Skills the Lab Values
clinical trial designpatient recruitmentdata managementplacebo control methodologybiostatisticspharmacological assessmentvascular health monitoringlongitudinal study analysis
Output against the department
Publications569top 9% of dept.63rd of 671
this lab
most publishedleast published
Citations29ktop 13% of dept.90th of 671
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.